To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Muse Effective For Many Impotent Men Who Fail Or Discontinue Injection Therapy URL: http://www.pslgroup.com/dg/8EEDE.htm Doctor's Guide July 16, 1998
MOUNTAIN VIEW, CA -- July 16, 1998 -- A study published in the journal Urology shows that Vivus, Inc.'s Muse(R) (alprostadil) is an effective treatment for erectile dysfunction in many men who have failed or discontinued intracavernous injection therapy. The study found that in patients who failed or discontinued prior injection therapy, 58 percent achieved an erection sufficient for intercourse on at least one of the four doses of Muse (125 mcg, 250 mcg, 500 mcg, and 1,000 mcg) in clinic. Forty-seven percent of these successful patients also reported intercourse during the home treatment phase of the study. As with other studies, most patients required the higher doses of Muse. The study evaluated the safety and efficacy of Muse in 452 patients diagnosed with chronic, organic erectile dysfunction who had a prior history of intracavernous injection therapy. A patient questionnaire revealed that 47 percent rated injection therapy as not effective or sometimes effective; the remaining patients rated injection therapy as effective. All patients had discontinued intracavernous treatment at least 30 days prior to this study and had been unable to achieve an erection sufficient for sexual intercourse without intracavernous injection therapy or other treatment for at least three months. "In the past, men who failed injection therapy were often offered penile implant surgery as their only option. This study demonstrated that Muse can be an effective option in men who fail to have an adequate response to injection therapy," said senior study author Kevin McVary, M.D., associate professor of urology at Northwestern University School of Medicine. "There are many algorithms for treating erectile dysfunction. These results show that success or failure with one treatment, intracavernosal injections, does not foretell response to another treatment, Muse. My hope is that these results will open up treatment options for patients who are not adequately treated." More information on: Muse, Vivus, Inc. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.